La Jolla Pharmaceutical Company (LJPC): Price and Financial Metrics


La Jolla Pharmaceutical Company (LJPC): $6.22

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LJPC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LJPC Stock Price Chart Interactive Chart >

Price chart for LJPC

LJPC Price/Volume Stats

Current price $6.22 52-week high $6.24
Prev. close $6.22 52-week low $3.07
Day low $6.20 Volume 267,600
Day high $6.24 Avg. volume 158,476
50-day MA $5.06 Dividend yield N/A
200-day MA $4.45 Market Cap 155.11M

La Jolla Pharmaceutical Company (LJPC) Company Bio


La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. The company was founded in 1989 and is based in San Diego, California.


LJPC Latest News Stream


Event/Time News Detail
Loading, please wait...

LJPC Latest Social Stream


Loading social stream, please wait...

View Full LJPC Social Stream

Latest LJPC News From Around the Web

Below are the latest news stories about LA JOLLA PHARMACEUTICAL CO that investors may wish to consider to help them evaluate LJPC as an investment opportunity.

Biotech M&A returns as Vertex, Innoviva make buys

Come, thou long-expected M&A. On Monday, Vertex Pharmaceuticals Inc. and Innoviva Inc. both announced that they were making acquisitions. Vertex (Nasdaq: VRTX) is set to buy ViaCyte, a cell therapy startup specializing in diabetes, for $320 million cash, while Innoviva will pay about $149 million for infectious diseases firm La Jolla Pharmaceutical Company (Nasdaq: LJPC).

Yahoo | July 12, 2022

How this Peninsula company is turning lung drug royalties into acquisitions

With the help of nearly $400 million in royalties from a well-known drug targeting asthma and COPD, the company wrapped up one acquisition and launched another.

Yahoo | July 11, 2022

Innoviva Bolsters Its Infectious Disease, Hospital Portfolio With La Jolla Deal

Innoviva Inc (NASDAQ: INVA) has agreed to acquire La Jolla Pharmaceutical Company (NASDAQ: LJPC) for $5.95 per share, representing a premium of approximately 70% to the 30-day volume-weighted average price. Innoviva will also pay an incremental $0.28 per share for additional cash proceeds received in connection with the divestiture of a non-core asset. The deal consideration of $6.23 per share in cash has an implied enterprise value of approximately $149 million. The FDA approved La Jolla's lead

Yahoo | July 11, 2022

Innoviva to Acquire La Jolla Pharmaceutical Company

BURLINGAME, Calif. & WALTHAM, Mass., July 11, 2022--Innoviva, Inc. (Nasdaq: INVA), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, and La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that they have entered into a definitive merger agreement whereby Innoviva will acquire

Yahoo | July 11, 2022

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress

WALTHAM, Mass., May 16, 2022--La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2022 and highlighted corporate progress.

Yahoo | May 16, 2022

Read More 'LJPC' Stories Here

LJPC Price Returns

1-mo N/A
3-mo N/A
6-mo 0.32%
1-year 34.34%
3-year -9.20%
5-year -82.65%
YTD N/A
2022 0.00%
2021 19.85%
2020 -1.27%
2019 -58.32%
2018 -70.70%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7154 seconds.